DE3406837C2 - - Google Patents

Info

Publication number
DE3406837C2
DE3406837C2 DE3406837A DE3406837A DE3406837C2 DE 3406837 C2 DE3406837 C2 DE 3406837C2 DE 3406837 A DE3406837 A DE 3406837A DE 3406837 A DE3406837 A DE 3406837A DE 3406837 C2 DE3406837 C2 DE 3406837C2
Authority
DE
Germany
Prior art keywords
diltiazem
arteriosclerosis
animals
administered
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3406837A
Other languages
German (de)
English (en)
Other versions
DE3406837A1 (de
Inventor
Azusa Minoh Osaka Jp Okaniwa
Hitoshi Tokio/Tokyo Jp Iwasaki
Kazuyuki Urawa Saitama Jp Kitamura
Takashi Kawagoe Saitama Jp Morita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Seiyaku Co Ltd
Original Assignee
Tanabe Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co Ltd filed Critical Tanabe Seiyaku Co Ltd
Publication of DE3406837A1 publication Critical patent/DE3406837A1/de
Application granted granted Critical
Publication of DE3406837C2 publication Critical patent/DE3406837C2/de
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
DE19843406837 1983-02-25 1984-02-24 Arteriosklerose-arzneimittel und -prophylaktikum Granted DE3406837A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58031515A JPS59157021A (ja) 1983-02-25 1983-02-25 動脈硬化症予防治療剤

Publications (2)

Publication Number Publication Date
DE3406837A1 DE3406837A1 (de) 1984-08-30
DE3406837C2 true DE3406837C2 (lv) 1990-12-20

Family

ID=12333337

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19843406837 Granted DE3406837A1 (de) 1983-02-25 1984-02-24 Arteriosklerose-arzneimittel und -prophylaktikum

Country Status (12)

Country Link
JP (1) JPS59157021A (lv)
BE (1) BE899000A (lv)
CH (1) CH658389A5 (lv)
DE (1) DE3406837A1 (lv)
DK (1) DK163712C (lv)
FR (1) FR2541577B1 (lv)
GB (1) GB2135192B (lv)
HK (1) HK45389A (lv)
IT (1) IT1178863B (lv)
NL (1) NL8400548A (lv)
SE (1) SE8400971L (lv)
SG (1) SG21189G (lv)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778791A (en) * 1986-05-16 1988-10-18 Tanabe Seiyaku Co., Ltd. Pharmaceutical composition for improving constitution of lipids in blood
JPS63107925A (ja) * 1986-05-23 1988-05-12 Tanabe Seiyaku Co Ltd 動脈硬化症予防・治療剤
JP2658783B2 (ja) * 1992-12-10 1997-09-30 田辺製薬株式会社 抗動脈硬化剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1236467A (en) * 1967-10-28 1971-06-23 Tanabe Seiyaku Co Benzothiazepine derivatives
US3562257A (en) * 1967-10-28 1971-02-09 Tanabe Seiyaku Co Benzothiazepine derivatives

Also Published As

Publication number Publication date
SE8400971D0 (sv) 1984-02-22
GB2135192B (en) 1986-10-22
DK103084A (da) 1984-08-26
SE8400971L (sv) 1984-08-26
JPS6358809B2 (lv) 1988-11-17
GB8405060D0 (en) 1984-04-04
SG21189G (en) 1990-01-26
GB2135192A (en) 1984-08-30
IT8467183A1 (it) 1985-08-24
DE3406837A1 (de) 1984-08-30
CH658389A5 (de) 1986-11-14
DK163712C (da) 1992-08-31
JPS59157021A (ja) 1984-09-06
IT8467183A0 (it) 1984-02-24
FR2541577A1 (fr) 1984-08-31
FR2541577B1 (fr) 1987-05-22
BE899000A (fr) 1984-06-18
HK45389A (en) 1989-06-16
NL8400548A (nl) 1984-09-17
DK103084D0 (da) 1984-02-24
IT1178863B (it) 1987-09-16
DK163712B (da) 1992-03-30

Similar Documents

Publication Publication Date Title
EP0180785B1 (de) Arzneimittel, enthaltend eine Kombination von Nitrendipin mit Enalapril, und Verfahren zu seiner Herstellung
DE2911670A1 (de) Arzneimittel zur therapeutischen behandlung von peripheren vaskularen erkrankungen
WO1987003480A2 (en) Medicament with anti-tumoral action containing hexadecylphosphocholine
EP0241809A1 (de) Synergistische Kombination von Amantadin und Selegilin
DE2523998A1 (de) Pharmazeutische zubereitung fuer die behandlung der schizophrenie
EP0607775A2 (de) Verwendung von Leflunomid zur Hemmung von Interleukin 1 beta
EP0185210B1 (de) Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Behandlung von an amyotropher Lateralsklerose Erkrankten
AT389998B (de) Verfahren zur herstellung einer analgetischen und antiinflammatorischen pharmazeutischen zubereitung
DE2514335C3 (de) Oral zu verabreichendes Arzneimittel mit Antiplasmin-Inhibitorwirkung
DE2854316C2 (lv)
DE3406837C2 (lv)
CH660556A5 (de) Therapeutische zubereitung zur behandlung von kardiovaskulaeren krankheiten.
DE69735892T2 (de) Heil-und vorbeugungsmittel für stomatitis
DE69630073T2 (de) (-)Hydroxycitrat enthaltende Verbindungen mit neuen therapeutischen Wirkungen
EP0207193A2 (de) Synergistische Kombination von Flupirtin und 4-Acetamido-phenol
DE3035494A1 (de) Carnitin enthaltendes arzneimittel zur behandlung von hyperlipidaemie und hyperlipoproteinaemie, sowie verwendung von carnitin zur herstellung eines solchen arzneimittels
DE3419425C2 (lv)
EP0557876B1 (de) Verwendung von Xanthinderivaten zur Behandlung von Muskelschädigungen nach vollständiger Unterbrechung der Blutzirkulation
EP0524512B1 (de) Antihypertensive Kombination
DE1963223A1 (de) Mittel zur Behandlung von Virusinfektionen
DE3141970A1 (de) Arzneimittel zur behandlung der durch den virus der herpes-gruppe erzeugten erkrankungen
AT390880B (de) Pharmazeutische verwendung einer 8-chlorobenzothiazepinverbindung
DE2808572C2 (de) Hämostatisches Mittel
DE2502678C3 (de) Arzneimittel zur Behandlung primärer und sekundärer Hyperlipoproteinämien
DE2810051A1 (de) Zubereitung fuer die behandlung von asthma

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee